OR WAIT null SECS
These are the authors of the new study included (left to right): Susana Valente, Cari F. Kessing and Chuan Li. Courtesy of Scripps Research Institute
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of the Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI associate professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
"No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo," Valente said. "When combining this drug with the standard cocktail of antiretrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present--it is really the proof-of-concept for a 'functional cure.'"
Valente, a pioneer in this new approach, calls it "Block-and-Lock"--the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
"Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation," Valente said. "It's important to note that our study uses the maximum tolerable dose of the drug--with virtually no side effects."
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
"This demonstrates the potential of 'block-and-lock' strategies," said TSRI Research Associate Cari F. Kessing, co-first author of the study. "This study shows that a 'functional cure' approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption."
"In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted," said the University of North Carolina's Christopher Nixon, another first author.
"We blocked Tat, and the cell's machinery did the rest," said TSRI research associate Chuan Li, a coauthor of the study. "The result was that the HIV promoter becomes repressed."
Valente pointed out that the animal models were exposed to just a single month of treatment. "That's a relatively short period of time," she said. "We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We're studying that now."
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
"This is the only class of drugs that stops infected cells from making viruses outright," said Valente. "All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production."
In addition to Valente, Kessing, Li and Nixon, other authors of the study, "In Vivo Suppression Of HIV Rebound By Didehydro-1 Cortistatin A, A 'Block-And-Lock' Strategy For HIV-1 Treatment," are Guillaume Mousseau and Mohammad Fallahi of TSRI; Perry M. Tsai, Phong T. Ho, Jenna B. Honeycutt and J. Victor Garcia of the University of North Carolina; and Hiroshi Takata and Lydie Trautmann of Walter Reed Army Institute of Research and the Henry M. Jackson Foundation for the Advancement of Military Medicine.
The study was supported by the National Institutes of Health (grants R01AI097012, R01AI118432, MH108179 and AI-111899), The Campbell Foundation and CARE, a Martin Delaney Collaboratory (1UM1AI126619).
Source: Scripps Research Institute